Completed PHASE2 NCT00179673

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Sponsor: Celgene

Conditions Non-Hodgkins Lymphoma

Interventions Lenalidomide

Updated 8 times since 2017 Last updated: May 9, 2025 Started: Jun 30, 2005 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This PHASE2 trial investigates Non-Hodgkins Lymphoma and is currently completed. Celgene leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Jun 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Jun 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene
Prologue Research International

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berkeley, United States , Boston, United States , Burnaby, Canada , Chicago, United States , Fountain Valley, United States , La Crosse, United States , London, Canada , Middletown, United States , North Vancouver, Canada , Omaha, United States and 5 more locations